Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
109 hedge funds and large institutions have $422M invested in Accelerate Diagnostics in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 10 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
6% more funds holding
Funds holding: 103 → 109 (+6)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
21% less capital invested
Capital invested by funds: $533M → $422M (-$111M)
75% less call options, than puts
Call options by funds: $1.21M | Put options by funds: $4.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$2.55M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.22M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.9M |
| 4 |
Morgan Stanley
New York
|
+$1.63M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.58M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.43M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$1.07M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$808K |
| 5 |
CCM
Coe Capital Management
Highland Park,
Illinois
|
-$756K |
AXDX Hedge Fund Activity: Q4 2016 in Review
109 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2016, worth a combined $422M — down 21% from $533M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AXDX positions and 10 closed out — a net gain of 7 holders — while 41 added to existing stakes and 24 trimmed.
The largest buyer was William Blair & Company, adding an estimated $2.55M. The largest seller was JP Morgan Chase, cutting an estimated $1.58M.
- 109 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2016, up from 103 in Q3 2016.
- Funds reported $422M of Accelerate Diagnostics stock for Q4 2016, down 21% quarter-over-quarter.
- 17 funds opened new Accelerate Diagnostics positions in Q4 2016 and 10 closed out, a net change of +7 holders.
- The largest Accelerate Diagnostics buyer in Q4 2016 was William Blair & Company, an estimated $2.55M added.
- The largest Accelerate Diagnostics seller in Q4 2016 was JP Morgan Chase, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2016.